Balance Sheet

Accounts Payables Accumulated Expenses Assets Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Current Assets Current Leases Current Taxes Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Liabilities from Discontinued Operations Long-Term Deferred Tax Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares

Cash Flow Statement

Growth Metrics

Cresco Labs (CRLBF) Cash & Equivalents (2019 - 2026)

Cresco Labs filings provide 7 years of Cash & Equivalents readings, the most recent being $32.3 million for Q1 2026.

On a quarterly basis, Cash & Equivalents changed N/A to $32.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was $32.3 million, a N/A change, with the full-year FY2025 number at $57.9 million, changed N/A from a year prior.
Cash & Equivalents hit $32.3 million in Q1 2026 for Cresco Labs, down from $57.9 million in the prior quarter.
In the past five years, Cash & Equivalents ranged from a high of $112.3 million in Q2 2024 to a low of $32.3 million in Q1 2026.
Median Cash & Equivalents over the past 4 years was $80.7 million (2023), compared with a mean of $76.5 million.